Multiple myeloma treatment transformed: A population-based study of changes in initial management approaches in the United States

Journal of Clinical Oncology

Volumn 31, Issue 16, 2013, Pages 1984-1989

  Warren, Joan L ^a   Harlan, Linda C ^a   Stevens, Jennifer ^b   Little, Richard F ^a   Abel, Gregory A ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INFORMATION MANAGEMENT SERVICES INC   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ICD-O-3; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MULTIPLE MYELOMA; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; TUMOR DIAGNOSIS; UNITED STATES; AFRICAN AMERICAN; ASIAN AMERICAN; AUTOTRANSPLANTATION; CANCER REGISTRY; CAUCASIAN; CLINICAL PRACTICE; ECONOMICS; EPIDEMIOLOGY; HISPANIC; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; RETROSPECTIVE STUDY; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME; UTILIZATION REVIEW;

ADULT; AFRICAN AMERICANS; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN AMERICANS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOXORUBICIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISPANIC AMERICANS; HUMANS; INSURANCE, HEALTH; LOGISTIC MODELS; MALE; MEDICAID; MEDICARE; MELPHALAN; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; SEER PROGRAM; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; UNITED STATES; VINCRISTINE;

MLCS; MLOWN;

EID: 84880652919     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.3323     Document Type: Article

References (26)

1. American Cancer Society: Cancer Facts and Figures, 2011. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf
2. Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2009_pops09/
3. Palumbo A, Attal M, Roussel M: Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: Maintenance therapy and overall survival. Clin Cancer Res 17:1253-1263, 2011
4. Kaya H, Peressini B, Jawed I, et al: Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol 95:64-70, 2012
5. Brenner H, Gondos A, Pulte D: Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111:2521-2526, 2008
6. Harousseau JL, Moreau P: Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 360:2645-2654, 2009
7. Moreau P, Avet-Loiseau H, Harousseau JL, et al: Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 29:1898-1906, 2011
8. Curtiss FR: Pharmacy benefit spending on oral chemotherapy drugs. J Manag Care Pharm 12:570-577, 2006
9. Pinsky B, Huang H, Teitelbaum A, et al: Multiple myeloma: Patient out-of-pocket costs and health care utilization. Blood 114, 2009 (abstr 1366)
10. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) program: Number of Persons by Race and Hispanic Ethnicity for SEER Participants (2010 Census Data). http://seer.cancer.gov/registries/data.html
11. Graubard BI, Korn EL: Predictive margins with survey data. Biometrics 55:652-659, 1999
12. Harlan LC, Greene AL, Clegg LX, et al: Insurance status and the use of guideline therapy in the treatment of selected cancers. J Clin Oncol 23: 9079-9088, 2005
13. Palumbo A, Bringhen S, Caravita T, et al: Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 367:825-831, 2006
14. Waage A, Gimsing P, Fayers P, et al: Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116:1405-1412, 2010
15. Mateos MV, Richardson PG, Schlag R, et al: Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28:2259-2266, 2010
16. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
17. Dimopoulos M, Spencer A, Attal M, et al: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357: 2123-2132, 2007
18. Richardson PG, Sonneveld P, Schuster MW, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498, 2005
19. Barlogie B, Kyle RA, Anderson KC, et al: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 24:929-936, 2006
20. Bladé J, Rosiñol L, Sureda A, et al: High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 106:3755-3759, 2005
21. Fermand JP, Katsahian S, Divine M, et al: High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 23: 9227-9233, 2005
22. Boukus ER, Cassil A, O’Malley AS: A Snapshot of U.S. Physicians: Key Findings from the 2008 Health Tracking Physician Survey. Data Bulletin No. 35, September 2009, Center for Studying Health System Change. http://www.hschange.com/CONTENT/1078/?words=au227
23. Joshua TV, Rizzo JD, Zhang MJ, et al: Access to hematopoietic stem cell transplantation: Effect of race and sex. Cancer 116:3469-3476, 2010
24. Waxman AJ, Mink PJ, Devesa SS, et al: Racial disparities in incidence and outcome in multiple myeloma: A population-based study. Blood 116: 5501-5506, 2010
25. McCarthy PL, Owzar K, Hofmeister CC, et al: Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1770-1781, 2012
26. Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520, 2008